Multiple sclerosis
Conditions
Interventions
The teriflunomide treatment group:None
Sponsors
The Affiliated Hospital of Xuzhou Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Age >= 18 years old, no gender restrictions; 2.Signing the informed consent form means that one can understand and comply with all the requirements of the research; 3.Diagnosed with relapsing multiple sclerosis according to the Chinese Guidelines for the Diagnosis and Treatment of Multiple Sclerosis (2023 Edition); 4.Receive treatment with teriflunomide; It is necessary to take Teriflunomide tablets (the prescription is issued by a doctor according to their clinical practice), and whether to prescribe Teriflunomide tablets is not related to the decision to include the patient in the current study.
Exclusion criteria
Exclusion criteria: 1.Currently participating in or having participated in any other interventional clinical trials within the past six months. 2.Women who are preparing for pregnancy, pregnant or breastfeeding; 3.Have a history of other active malignant diseases within 2 years before entering the study; 4.According to the investigator's judgment, the subject is not suitable for study observation; 5.Age over 75 years (including 75 years).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence of adverse reactions;Annual recurrence rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Severity of the disease;The types and incidence rates of new adverse reactions; | — |
Countries
China
Contacts
Public ContactYong Zhang
The Affiliated Hospital of Xuzhou Medical University
Outcome results
None listed